Literature DB >> 29021226

Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.

Wayne R Fitzgibbon1, Yujing Dang1, Marlene A Bunni1, Catalin F Baicu2, Michael R Zile2, Adam E Mullick3, Takamitsu Saigusa1,4.   

Abstract

The intrarenal renin angiotensin system (RAS) is activated in polycystic kidney disease. We have recently shown in the Pkd1 mouse that Gen 2 antisense oligonucleotide (ASO), which suppresses angiotensinogen (Agt) synthesis, is efficacious in slowing kidney cyst formation compared with lisinopril. The aim of this current study was to determine 1) if unilateral nephrectomy accelerates cystogenesis in Pkd1 mice (as previously shown in cilia knockout mice) and 2) whether Agt ASO can slow the progression in this accelerated cystic mouse model. Adult Pkd1 conditional floxed allele mice expressing cre were administered tamoxifen, resulting in global knockout of Pkd1. Three weeks after tamoxifen injection, mice underwent left unilateral nephrectomy. Mice were then treated with Agt ASO (75 mg/kg per week) or aliskiren (20 mg/kg per day)+Agt ASO or control for 8 wk. Unilateral nephrectomy accelerated kidney cyst formation compared with nonnephrectomized mice. Both Agt ASO and Aliskiren+Agt ASO treatments significantly reduced plasma and urinary Agt levels. Blood pressure was lowest in Aliskiren+Agt ASO mice among all treatment groups, and the control group had the highest blood pressure. All mice developed significant kidney cysts at 8 wk after nephrectomy, but Agt ASO and Aliskiren+Agt ASO groups had fewer kidney cysts than controls. Renal pAkt, pS6 levels, and apoptosis were significantly suppressed in those receiving Agt ASO compared with controls. These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mammalian target of rapamycin pathway, and cell proliferation.

Entities:  

Keywords:  ADPKD, angiotensinogen; oligonucleotide; polycystic kidney disease

Mesh:

Substances:

Year:  2017        PMID: 29021226      PMCID: PMC5866454          DOI: 10.1152/ajprenal.00389.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  38 in total

1.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Svend Strandgaard; Anne-Lise Kamper; Giuseppe Maschio; Gavin Becker; Ronald D Perrone; Andrew S Levey
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

3.  Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage.

Authors:  Kelli M Sas; Hong Yin; Wayne R Fitzgibbon; Catalin F Baicu; Michael R Zile; Stacy L Steele; May Amria; Takamitsu Saigusa; Jason Funk; Marlene A Bunni; Gene P Siegal; Brian J Siroky; John J Bissler; P Darwin Bell
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-22

4.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

5.  Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Abdullah Ozkok; Qian Wang; Adam E Mullick; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2014-12-23

Review 6.  mTOR signaling in polycystic kidney disease.

Authors:  Oxana Ibraghimov-Beskrovnaya; Thomas A Natoli
Journal:  Trends Mol Med       Date:  2011-07-19       Impact factor: 11.951

Review 7.  Role of angiotensin II in tubulointerstitial injury.

Authors:  Z Cao; M E Cooper
Journal:  Semin Nephrol       Date:  2001-11       Impact factor: 5.299

8.  A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo.

Authors:  Klaus B Piontek; David L Huso; Alexander Grinberg; Lijuan Liu; Djahida Bedja; Haidan Zhao; Kathleen Gabrielson; Feng Qian; Changlin Mei; Heiner Westphal; Gregory G Germino
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

9.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

10.  The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.

Authors:  Mahmoud Loghman-Adham; Carlos E Soto; Tadashi Inagami; Lisa Cassis
Journal:  Am J Physiol Renal Physiol       Date:  2004-06-08
View more
  10 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

2.  Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury.

Authors:  Ehtesham Arif; Ashish K Solanki; Pankaj Srivastava; Bushra Rahman; Wayne R Fitzgibbon; Peifeng Deng; Milos N Budisavljevic; Catalin F Baicu; Michael R Zile; Judit Megyesi; Michael G Janech; Sang-Ho Kwon; Justin Collier; Rick G Schnellmann; Deepak Nihalani
Journal:  Kidney Int       Date:  2019-05-06       Impact factor: 10.612

3.  Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC).

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Tengis S Pavlov; Elena Isaeva; Christine A Klemens; Jessica Johnson; Pengyuan Liu; Alison J Kriegel; Alexander Staruschenko
Journal:  EBioMedicine       Date:  2019-02-08       Impact factor: 11.205

4.  Interferon Regulatory Factor-5 in Resident Macrophage Promotes Polycystic Kidney Disease.

Authors:  Kurt A Zimmerman; Jifeng Huang; Lan He; Dustin Z Revell; Zhang Li; Jung-Shan Hsu; Wayne R Fitzgibbon; E Starr Hazard; Gary Hardiman; Michal Mrug; P Darwin Bell; Bradley K Yoder; Takamitsu Saigusa
Journal:  Kidney360       Date:  2020-03-26

Review 5.  Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis.

Authors:  Marijn F Stokman; Sophie Saunier; Alexandre Benmerah
Journal:  Front Cell Dev Biol       Date:  2021-05-13

Review 6.  Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Authors:  Chia-Hua Wu; Ya Wang; Murong Ma; Adam E Mullick; Rosanne M Crooke; Mark J Graham; Alan Daugherty; Hong S Lu
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.976

Review 7.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Authors:  Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

8.  Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hayne Cho Park; Juhee Kim; AJin Cho; Do Hyoung Kim; Young Ki Lee; Hyunjin Ryu; Hyunsuk Kim; Kook Hwan Oh; Yun Kyu Oh; Young Hwan Hwang; Kyu Beck Lee; Soo Wan Kim; Yeong Hoon Kim; Joongyub Lee; Curie Ahn
Journal:  J Korean Med Sci       Date:  2020-06-08       Impact factor: 2.153

Review 9.  Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases.

Authors:  Valeriia Y Vasileva; Regina F Sultanova; Anastasia V Sudarikova; Daria V Ilatovskaya
Journal:  Front Physiol       Date:  2021-09-08       Impact factor: 4.566

Review 10.  Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.

Authors:  Roberto Pagliarini; Christine Podrini
Journal:  Front Med (Lausanne)       Date:  2021-11-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.